Know Cancer

or
forgot password

Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.


N/A
18 Years
N/A
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.


Inclusion Criteria:



- Eligible for breast conserving therapy i.e. histologically proven breast cancer

- Operable disease

- Visible mass on mammography or ultrasound > 0.5 c

Exclusion Criteria:

- All contra-indications for breast conserving therapy, i.e. previous radiotherapy of
the breast, multicentricity, inoperable disease, or too large tumor in a relatively
too small breast, pregnancy.

- Contra-indications for intravenous contrast, i.e. iodine allergy, renal malfunction
(kreatinine clearance < 60 ml/min), , previous allergic reaction to i.v. contrast, M.
Kahler, use of NSAIDs, Diuretics or Metformine.

- Absence of tumor mass > 0.5 cm on conventional mammography or ultrasound

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

The percentage of the PTV-2 receiving < 85% of the dose, if treated with the RT-plan for PTV-1.

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Liesbeth Boersma

Investigator Role:

Principal Investigator

Investigator Affiliation:

MAASTRO Clinic

Authority:

Netherlands: Medical Ethics Review Committee (METC)

Study ID:

Delineation of tumourbed mamma

NCT ID:

NCT00721058

Start Date:

August 2008

Completion Date:

Related Keywords:

  • Breast Cancer
  • Eligible
  • Operable
  • Disease
  • Conserving
  • Therapy
  • Visible mass on mammography
  • Ultrasound > 0.5 cm
  • Histologically
  • Proven
  • Breast Neoplasms

Name

Location